| Protein Name: | Glucose transporter I (P11166) |
|---|---|
| Gene Name: | SLC2A1 |
| Description: | Solute carrier family 2, facilitated glucose transporter member 1 (Glucose transporter type 1, erythrocyte/brain) (HepG2 glucose transporter) |
| PDB ID: | 1SUK |
| Protein Family: | |
| Protein Category: | Transporters |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Captopril | Ill Effects | Decreased expression of glucose transporter I may be associated with increased intracellular glucose and the resultant ill effects@captopril reversed the above high glucose-induced effects partly by enhancing glucose transporter I and II messenger RNA expressions. [ ADR Type 1 ] | Captopril reverses high glucose-induced effects on LLC-PK1 cells partly by enhancing facilitative glucose transporter messenger RNA expressions |
| Troglitazone | Beneficial For The Diabetic Heart | Troglitazone induced a dose-dependent increase in 2-deoxyglucose uptake reaching a 40-fold stimulation at 5 mumol/l@This was paralleled by a dose-dependent increase of Glucose transporter-1 (GLUT1) and GLUT4 protein expression;troglitazone exerts multiple effects on cardiomyocytes involving inhibition of PKC and regulation of Glucose transporter expression and distribution which may be beneficial for the diabetic heart and that modulation of PKC-activity could be relevant for improving insulin action in muscle tissue. [ ADR Type 1 ] | Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes |
This panel provides information on drug category
| Toxicity | Source |
|---|